Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 196

1.

The molecular basis of breast cancer pathological phenotypes.

Heng YJ, Lester SC, Tse GM, Factor RE, Allison KH, Collins LC, Chen YY, Jensen KC, Johnson NB, Jeong JC, Punjabi R, Shin SJ, Singh K, Krings G, Eberhard DA, Tan PH, Korski K, Waldman FM, Gutman DA, Sanders M, Reis-Filho JS, Flanagan SR, Gendoo DM, Chen GM, Haibe-Kains B, Ciriello G, Hoadley KA, Perou CM, Beck AH.

J Pathol. 2016 Nov 14. doi: 10.1002/path.4847. [Epub ahead of print]

PMID:
27861902
2.

Mutation Yield of a 34-Gene Solid Tumor Panel in Community-Based Tumor Samples.

Sanders H, Qu K, Li H, Ma L, Barlan C, Zhang X, Prentice J, Wolfson D, Crossley B, Sferruzza A, Sninsky J, Ross D, Grupe A, Catanese J, Hantash F, Waldman F.

Mol Diagn Ther. 2016 Jun;20(3):241-53. doi: 10.1007/s40291-016-0197-0.

PMID:
27084556
3.

Mutational Analysis in Pediatric Thyroid Cancer and Correlations with Age, Ethnicity, and Clinical Presentation.

Nikita ME, Jiang W, Cheng SM, Hantash FM, McPhaul MJ, Newbury RO, Phillips SA, Reitz RE, Waldman FM, Newfield RS.

Thyroid. 2016 Feb;26(2):227-34. doi: 10.1089/thy.2015.0401.

4.

Cost Effectiveness of Sequencing 34 Cancer-Associated Genes as an Aid for Treatment Selection in Patients with Metastatic Melanoma.

Li Y, Bare LA, Bender RA, Sninsky JJ, Wilson LS, Devlin JJ, Waldman FM.

Mol Diagn Ther. 2015 Jun;19(3):169-77. doi: 10.1007/s40291-015-0140-9.

5.

Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum.

Dinney CP, Hansel D, McConkey D, Shipley W, Hagan M, Dreicer R, Lerner S, Czerniak B, Waldman F, Groshen S, True LD, Petricoin E, Theodorescu D, Hruszkewycz A, Bajorin D.

Urol Oncol. 2014 Nov;32(8):1108-15. doi: 10.1016/j.urolonc.2013.10.021. Review.

6.

An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk.

Yau C, Sninsky J, Kwok S, Wang A, Degnim A, Ingle JN, Gillett C, Tutt A, Waldman F, Moore D, Esserman L, Benz CC.

Breast Cancer Res. 2013;15(5):R103.

7.

Detection of BRAF V600 mutations in metastatic melanoma: comparison of the Cobas 4800 and Sanger sequencing assays.

Qu K, Pan Q, Zhang X, Rodriguez L, Zhang K, Li H, Ho A, Sanders H, Sferruzza A, Cheng SM, Nguyen D, Jones D, Waldman F.

J Mol Diagn. 2013 Nov;15(6):790-5. doi: 10.1016/j.jmoldx.2013.07.003.

PMID:
23994118
8.

Florid lobular carcinoma in situ: molecular profiling and comparison to classic lobular carcinoma in situ and pleomorphic lobular carcinoma in situ.

Shin SJ, Lal A, De Vries S, Suzuki J, Roy R, Hwang ES, Schnitt SJ, Waldman FM, Chen YY.

Hum Pathol. 2013 Oct;44(10):1998-2009. doi: 10.1016/j.humpath.2013.04.004.

PMID:
23809857
9.

FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast.

Lal A, Chan L, Devries S, Chin K, Scott GK, Benz CC, Chen YY, Waldman FM, Hwang ES.

Breast Cancer Res Treat. 2013 Jun;139(2):381-90. doi: 10.1007/s10549-013-2556-4.

PMID:
23712790
10.

Genomic aberrations in normal tissue adjacent to HER2-amplified breast cancers: field cancerization or contaminating tumor cells?

Sadanandam A, Lal A, Benz SC, Eppenberger-Castori S, Scott G, Gray JW, Spellman P, Waldman F, Benz CC.

Breast Cancer Res Treat. 2012 Dec;136(3):693-703. doi: 10.1007/s10549-012-2290-3.

11.

Genomic copy number alterations in clear cell renal carcinoma: associations with case characteristics and mechanisms of VHL gene inactivation.

Moore LE, Jaeger E, Nickerson ML, Brennan P, De Vries S, Roy R, Toro J, Li H, Karami S, Lenz P, Zaridze D, Janout V, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Linehan WM, Merino M, Simko J, Pfeiffer R, Boffetta P, Hewitt S, Rothman N, Chow WH, Waldman FM.

Oncogenesis. 2012 Jun 25;1:e14. doi: 10.1038/oncsis.2012.14.

12.

Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.

Moore LE, Nickerson ML, Brennan P, Toro JR, Jaeger E, Rinsky J, Han SS, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Schmidt LS, Lenz P, Karami S, Linehan WM, Merino M, Chanock S, Boffetta P, Chow WH, Waldman FM, Rothman N.

PLoS Genet. 2011 Oct;7(10):e1002312. doi: 10.1371/journal.pgen.1002312.

13.

Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues.

Rimm DL, Nielsen TO, Jewell SD, Rohrer DC, Broadwater G, Waldman F, Mitchell KA, Singh B, Tsongalis GJ, Frankel WL, Magliocco AM, Lara JF, Hsi ED, Bleiweiss IJ, Badve SS, Chen B, Ravdin PM, Schilsky RL, Thor A, Berry DA; Cancer and Leukemia Group B Pathology Committee..

J Clin Oncol. 2011 Jun 1;29(16):2282-90. doi: 10.1200/JCO.2010.33.2023.

14.

Genomic alterations and phenotype of large compared to small high-grade ductal carcinoma in situ.

Hwang ES, Lal A, Chen YY, DeVries S, Swain R, Anderson J, Roy R, Waldman FM.

Hum Pathol. 2011 Oct;42(10):1467-75. doi: 10.1016/j.humpath.2011.01.002.

PMID:
21496874
15.

A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer.

Yau C, Esserman L, Moore DH, Waldman F, Sninsky J, Benz CC.

Breast Cancer Res. 2010;12(5):R85. doi: 10.1186/bcr2753.

16.

Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.

Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, Sanchez H, Jimenez C, Stewart K, Chew K, Ljung BM, Tlsty TD.

J Natl Cancer Inst. 2010 May 5;102(9):627-37. doi: 10.1093/jnci/djq101. Erratum in: J Natl Cancer Inst. 2010 Jul 7;102(13):993.

17.

Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery.

Tejpar S, Bertagnolli M, Bosman F, Lenz HJ, Garraway L, Waldman F, Warren R, Bild A, Collins-Brennan D, Hahn H, Harkin DP, Kennedy R, Ilyas M, Morreau H, Proutski V, Swanton C, Tomlinson I, Delorenzi M, Fiocca R, Van Cutsem E, Roth A.

Oncologist. 2010;15(4):390-404. doi: 10.1634/theoncologist.2009-0233. Review.

18.

TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern Europe.

SzymaƄska K, Moore LE, Rothman N, Chow WH, Waldman F, Jaeger E, Waterboer T, Foretova L, Navratilova M, Janout V, Kollarova H, Zaridze D, Matveev V, Mates D, Szeszenia-Dabrowska N, Holcatova I, Bencko V, Le Calvez-Kelm F, Villar S, Pawlita M, Boffetta P, Hainaut P, Brennan P.

Cancer Lett. 2010 Jul 1;293(1):92-8. doi: 10.1016/j.canlet.2009.11.024.

PMID:
20137853
19.

Similarity in genetic alterations between paired well-differentiated and dedifferentiated components of dedifferentiated liposarcoma.

Horvai AE, DeVries S, Roy R, O'Donnell RJ, Waldman F.

Mod Pathol. 2009 Nov;22(11):1477-88. doi: 10.1038/modpathol.2009.119.

20.

Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast.

Chen YY, Hwang ES, Roy R, DeVries S, Anderson J, Wa C, Fitzgibbons PL, Jacobs TW, MacGrogan G, Peterse H, Vincent-Salomon A, Tokuyasu T, Schnitt SJ, Waldman FM.

Am J Surg Pathol. 2009 Nov;33(11):1683-94. doi: 10.1097/PAS.0b013e3181b18a89.

Items per page

Supplemental Content

Loading ...
Support Center